Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.47 |
| ▸ | VEGFA | P15692 | 4/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2035696 | 0.84 | HSPB1 (0.53) | PPARGVEGFAPDE7AHSPB1ALDH1A1 | |
| SCHEMBL11092359 | 0.83 | PDE7A (0.53) | CYP1A2CYP2C9CYP2C19EPAS1VEGFA | |
| SCHEMBL2031919 | 0.83 | PDE7A (0.60) | PPARGCYP1A2CYP2C9CYP2C19PDE7A | |
| SCHEMBL29519502 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19EPAS1VEGFA | |
| SCHEMBL8141281 | 0.81 | HSPB1 (0.57) | CYP1A2CYP2C9CYP2C19EPAS1VEGFA | |
| SCHEMBL4694599 | 0.81 | PPARG (0.49) | PPARGPDE7AHSPB1ALDH1A1MAPT | |
| SCHEMBL2030201 | 0.81 | PPARG (0.47) | PPARGEPAS1VEGFAPDE7AHSPB1 | |
| SCHEMBL31457196 | 0.80 | HSPB1 (0.57) | CYP1A2CYP2C9CYP2C19EPAS1PDE7A | |
| SCHEMBL2034854 | 0.80 | PPARG (0.50) | PPARGCYP1A2CYP2C9CYP2C19PDE7A | |
| SCHEMBL10508154 | 0.80 | CYP1A2 (0.48) | CYP1A2CYP2C9CYP2C19EPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1053227-B1 | PPAR-GAMMA MODULATORS | AMGEN INC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-7439242-B2 | PPARγ modulators | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20030088103-A1 | PPARgamma modulators | TULARIK INC. (US) | 2003-05-08 | — | — | US | disclosed |
| US-20010027200-A1 | PPARgamma modulators | TULARIK INC. | 2001-10-04 | — | — | US | disclosed |
| US-6200995-B1 | PYRIDYLOXYBENZENESULFONAMIDE DERIVATIVES; DIABETES, OBESITY | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030088103-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | PPARG 1/4885CYP1A2 1014/4885CYP2C9 1917/4885 |
| US-20010027200-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | PPARG 1/4885CYP1A2 1014/4885CYP2C9 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.